Agilon Health
AGL
85.70
+2.30
+2.76%
Agilon Health
US · AGL
#3034 by market cap
Listed 2021
85.70
+2.30
+2.76%
Live - 5344 symbols - heartbeat 69s ago
· 2026-10-08 08:02
Pre-market
85.90
+0.23%
After-hours
85.70
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -6.03
- P/Bi
- 6.32
- EPSi
- -23.75
- Div yieldi
- 0.00%
- 52W posi
- 62%
Reader sentiment
Are you bullish or bearish on AGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.15, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -2.11% YoY
Margins
- Gross margin
- -2.70%
- Operating margin
- -7.20%
- Net margin
- -6.60%
Key ratios & quality
- Enterprise valuei
- 1.19B
- Altman Z-Scorei
- 2.15
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B |
| Gross profit | 28.51M | 94.15M | 65.74M | 111.36M | 69.67M | 4.84M | -160.02M |
| Selling & admin expenses | 122.83M | 137.29M | 427.50M | 207.79M | 285.76M | 268.91M | 238.54M |
| Research & development | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -106.57M | -56.67M | -372.24M | -105.38M | -232.13M | -288.53M | -427.15M |
| Pretax profit | -114.69M | -62.34M | -382.98M | -90.67M | -194.46M | -248.83M | -404.10M |
| Tax | -232.00K | 865.00K | 886.00K | 1.64M | 791.00K | 1.45M | 1.25M |
| Net profit | -282.74M | -60.05M | -406.79M | -106.86M | -262.80M | -260.10M | -391.35M |
| Basic EPS | -18 | -4 | -27 | -7 | -16 | -16 | -24 |
| Diluted EPS | -18.40 | -3.90 | -27.25 | -6.50 | -16.00 | -15.75 | -23.75 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.53B | 1.39B | 1.44B | 1.57B | 1.42B | 1.49B |
| Gross profit | 50.72M | -52.43M | -67.65M | -90.67M | 65.02M | 107.14M |
| Selling & admin expenses | 65.96M | 56.28M | 56.20M | 60.10M | 54.23M | 88.51M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -22.11M | -116.03M | -131.27M | -157.74M | 4.00M | 11.77M |
| Pretax profit | -1.69M | -104.31M | -110.54M | -187.56M | 29.94M | 17.58M |
| Tax | 196.00K | 62.00K | -331.00K | 1.32M | 28.00K | -375.00K |
| Net profit | 12.11M | -104.37M | -110.21M | -188.88M | 48.92M | 17.96M |
| Basic EPS | 1 | -6 | -7 | -12 | 3 | 1 |
| Diluted EPS | 0.73 | -6.31 | -6.75 | -11.50 | 2.94 | 1.04 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 245.53M | 294.20M | 1.37B | 1.45B | 1.48B | 1.46B | 1.10B |
| Cash & ST investments | 123.63M | 106.80M | 1.04B | 877.20M | 488.34M | 399.97M | 285.14M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 402.79M | 446.36M | 1.59B | 1.70B | 1.74B | 1.73B | 1.27B |
| Total current liabilities | 199.61M | 266.84M | 356.96M | 535.09M | 977.16M | 1.15B | 1.08B |
| Short-term debt | 3.04M | 3.04M | 5.00M | 5.00M | -- | -- | 19.24M |
| Long-term debt | 67.14M | 64.67M | 43.40M | 38.48M | 32.31M | 34.90M | 15.75M |
| Total liabilities | 634,822,000.00 | 731,091,000.00 | 494,656,000.00 | 656,859,000.00 | 1,079,845,000.00 | 1,263,031,000.00 | 1,144,556,000.00 |
| Total equity | -232.03M | -284.73M | 1.09B | 1.04B | 661.02M | 470.95M | 126.73M |
| Retained earnings | -491.14M | -551.19M | -957.68M | -1.06B | -1.33B | -1.59B | -1.98B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.65B | 1.45B | 1.34B | 1.10B | 1.32B | 1.42B |
| Cash & ST investments | 367.08M | 327.00M | 310.85M | 285.14M | 231.41M | 185.63M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.93B | 1.71B | 1.60B | 1.27B | 1.50B | 1.59B |
| Total current liabilities | 1.37B | 1.25B | 1.24B | 1.08B | 1.27B | 1.31B |
| Short-term debt | 34.92M | 34.95M | 34.97M | 19.24M | 14.75M | 14.92M |
| Long-term debt | -- | -- | -- | 15.75M | 15.28M | 15.38M |
| Total liabilities | 1,432,607,000.00 | 1,303,966,000.00 | 1,290,168,000.00 | 1,144,556,000.00 | 1,323,505,000.00 | 1,363,809,000.00 |
| Total equity | 500.25M | 408.93M | 306.08M | 126.73M | 181.43M | 227.53M |
| Retained earnings | -1.57B | -1.68B | -1.79B | -1.98B | -1.93B | -1.91B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -103.86M | -53.20M | -148.16M | -130.81M | -156.20M | -57.78M | -105.76M |
| Depreciation & amortization | 41.41M | 14.10M | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M |
| Free cash flow | -107.77M | -55.55M | -161.59M | -163.47M | -187.01M | -99.06M | -148.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 180.19M | 27.66M | 1.19B | 33.06M | -188.13M | 1.17M | -2.99M |
| Ending cash balance | 145.61M | 139.10M | 1.05B | 507.68M | 114.33M | 193.86M | 173.71M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.99M | -35.09M | -18.15M | -20.54M | 23.73M | -57.30M |
| Depreciation & amortization | 6.88M | 7.32M | 7.43M | 6.97M | 6.79M | 6.86M |
| Free cash flow | -42.87M | -41.02M | -34.69M | -30.30M | 20.60M | -61.60M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -161.00K | -2.58M | -236.00K | -17.00K | -35.00K | 4.63M |
| Ending cash balance | 138.62M | 171.42M | 171.68M | 173.71M | 211.57M | 178.81M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -100.72 | -9.99 | -30.84 | -45.93 | -130.95 |
| ROA %i | -70.16 | -14.14 | -40.00 | -6.49 | -15.27 | -14.97 | -26.04 |
| ROIC %i | -- | -- | -85.83 | -9.18 | -28.50 | -41.93 | -110.67 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -63.69 |
| EBIT margin %i | -13.30 | -4.45 | -21.73 | -3.74 | -4.35 | -4.00 | -6.70 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.23 | 1.10 | 3.83 | 2.71 | 1.51 | 1.27 | 1.02 |
| Quick ratioi | 1.09 | 0.94 | 3.74 | 2.56 | 1.46 | 1.23 | 0.89 |
| Debt / assetsi | 19.35 | 16.40 | 3.55 | 3.10 | 2.48 | 2.39 | 2.90 |
| LT debt / equityi | -- | -- | 4.70 | 4.57 | 6.53 | 8.81 | 13.87 |
| Interest coveragei | -11.65 | -6.66 | -64.83 | -22.36 | -28.21 | -39.28 | -59.85 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 44.33 | 52.45 | 58.52 | 35.43 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -40.68 | -58.16 | -69.98 | -130.95 | -104.02 | -72.97 |
| ROA %i | -11.39 | -16.29 | -16.72 | -26.04 | -20.63 | -14.06 |
| ROIC %i | -37.03 | -52.97 | -60.81 | -110.67 | -92.56 | -64.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.13 | -5.45 | -5.35 | -6.70 | -6.28 | -4.11 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.20 | 1.16 | 1.08 | 1.02 | 1.04 | 1.08 |
| Quick ratioi | 1.17 | 1.10 | 1.01 | 0.89 | 0.89 | 0.95 |
| Debt / assetsi | 2.17 | 2.42 | 2.33 | 2.90 | 2.22 | 2.10 |
| LT debt / equityi | 1.42 | 1.57 | 0.70 | 13.87 | 10.28 | 8.14 |
| Interest coveragei | -38.58 | -51.16 | -48.42 | -59.85 | -52.69 | -34.93 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Medical services revenue is the largest reported line at 99.88% of revenue, across 2 reported segments.
- The next-largest line, Other Operating Revenue, is a distant second at 0.12% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Medical services revenue99.88%
Other Operating Revenue0.12%
Quote time 2026-10-08 08:02:55 · For reference only, not investment advice and not tailored to your situation.